TRI-LINYAH
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRI-LINYAH (TRI-LINYAH).
Combination hormonal contraceptive: ethinyl estradiol and norgestimate. Suppresses gonadotropin release, inhibiting ovulation; also increases cervical mucus viscosity and alters endometrial morphology.
| Metabolism | Ethinyl estradiol: primarily metabolized by CYP3A4, undergoes hydroxylation and conjugation. Norgestimate: rapidly hydrolyzed to norelgestromin and further metabolized by CYP3A4, CYP2C9, and CYP2C19. |
| Excretion | Ethinyl estradiol is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates; norgestimate is primarily eliminated via renal excretion (46%) and fecal excretion (47%) as metabolites. |
| Half-life | Ethinyl estradiol: terminal half-life approximately 17 hours (range 13–27 hours), supporting once-daily dosing; norgestimate's active metabolite norelgestromin: terminal half-life approximately 28 hours. |
| Protein binding | Ethinyl estradiol: ~97% bound to serum albumin; norelgestromin: ~99% bound, primarily to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Ethinyl estradiol: Vd approximately 2–4 L/kg, indicating extensive tissue distribution; norelgestromin: Vd approximately 2.7 L/kg. |
| Bioavailability | Oral bioavailability of ethinyl estradiol: ~55% (with interindividual variability); norgestimate: rapidly and extensively converted to active norelgestromin; absolute bioavailability not reported due to extensive first-pass metabolism. |
| Onset of Action | Oral administration: contraceptive effects require 7 days of continuous dosing to achieve therapeutic serum concentrations; immediate if starting on day 1 of menstrual cycle (no backup needed). |
| Duration of Action | Contraceptive protection maintained for 24 hours post-dose; consistent once-daily dosing required; missed doses reduce efficacy. |
One tablet orally once daily for 21 days, followed by 7 placebo tablets. Each tablet contains 0.035 mg ethinyl estradiol and 0.180/0.215/0.250 mg norgestimate.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure. |
| Liver impairment | Contraindicated in acute hepatic disease or severe hepatic impairment. For Child-Pugh Class B or C, contraindicated. No data for mild impairment. |
| Pediatric use | Not indicated for females with menarche before age 18. Use same dosing as adults post-menarche. |
| Geriatric use | Not indicated for postmenopausal women. No specific dose adjustments for elderly, but consider increased risk of thromboembolism, cardiovascular disease, and contraindication in women >35 years who smoke 15+ cigarettes daily. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRI-LINYAH (TRI-LINYAH).
| Breastfeeding | Excreted in breast milk; M/P ratio for ethinyl estradiol is approximately 0.2-0.5, for levonorgestrel 0.1-0.3. May reduce milk production and quality; use only if benefits outweigh risks, preferably after weaning. |
| Teratogenic Risk | TRI-LINYAH (levonorgestrel/ethinyl estradiol) is contraindicated in pregnancy. First trimester: no increased risk of major birth defects from inadvertent use, but intended use contraindicated. Second and third trimesters: known risks including feminization of male fetuses, cardiovascular and neurologic effects from progestin exposure, and estrogenic effects on fetal development. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
| Serious Effects |
Thrombophlebitis or thromboembolic disorders, cerebral vascular/coronary artery disease, known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer, hepatic tumor or active liver disease, hypersensitivity to any component, current or past history of migraine with focal neurological symptoms (if age ≥35), diabetes with vascular involvement, uncontrolled hypertension, cigarette smoking in women >35
| Precautions | Thrombotic disorders (venous and arterial), cigarette smoking, elevated blood pressure, gallbladder disease, carbohydrate/lipid effects, headache, hepatic neoplasia, ocular disturbances, interactions with other drugs. |
Loading safety data…
| Fetal Monitoring | Monitor blood pressure at each prenatal visit; assess liver function if signs of cholestasis; monitor glucose tolerance if history of gestational diabetes; ultrasound for fetal development if exposure occurs. |
| Fertility Effects | Temporary suppression of ovulation; normal fertility returns upon discontinuation. No permanent adverse effects on female fertility; no data on male fertility. |